Welcome to the BreatheDMD Site
BreatheDMD enrollment is suspended as of November 19, 2019 until the SIDEROS clinical trial is fully enrolled. All current patients enrolled in the BreatheDMD program will continue receiving investigational idebenone, but no new patients will be enrolled and no new sites will be opened at this time. Please see the full announcement here. If you are interested in being a part of the SIDEROS trial or have questions about the trial, please contact us at email@example.com. To learn more about the trial, talk with your health care provider and visit www.siderosdmd.com and www.clinicaltrials.gov NCT 02814019.
Ready to get started?
What is the BreatheDMD Program?
BreatheDMD is an expanded access program that has been authorized by the Food and Drug Administration (FDA). Expanded access is the use of an investigational medical product (one that has not been approved by the FDA) outside of a clinical trial for a serious disease or condition for which there is no comparable or satisfactory therapy available.
The request must be initiated by a patient’s treating physician, and is applicable when there is an unmet medical need. BreatheDMD will allow eligible patients with DMD in the US to be treated with idebenone, an investigational medicine currently in development for DMD.
Expanded Access Program (EAP)
Idebenone is a medicine that is under investigation for the treatment of DMD. It has not been approved by the US Food and Drug Administration (FDA) and the safety and efficacy continue to be evaluated in clinical trials.
To find your closest BreatheDMD center, roll your mouse over the map below. If your treating physician is not listed here, you may ask them to refer you to your nearest BreatheDMD center.
Call (877) 768-4303